Pneumococcal Vaccines Market

Report Overview

The global pneumococcal vaccines market was pegged at US$ 8.3 billion in 2021 and is expected to witness a CAGR of 5.20 % during the forecast period.

Market Fundamentals

Pneumococcal vaccines also called as pneumonia vaccines act against bacterium streptococcus pneumoniae defending from serious and fatal pneumococcal infections. The bacterium streptococcus pneumoniae can lead to pneumonia, blood poisoning and meningitis. The vaccine comprises pneumococcal capsular polysaccharide conjugated with a protein carrier. This results in a T-cell related immune reaction. Anyone aged 2 to 64 with a health condition that puts them at risk of pneumococcal infections are recommended to take the vaccine.

[345234234] 

Market Dynamics

Globally, the pneumococcal vaccine demand is increasing due to increased cases of pneumococcal infections, an ageing population that is more susceptible to infections, and increased vaccine awareness. Furthermore, the introduction of novel vaccines can be viewed as a market growth opportunity. However, growing antivaxxer population is a challenging factor for the market and the reliance on a T-cell response and the lower serotype coverage of the vaccine is a restraining factor for the global market.

Market Ecosystem

The global pneumococcal vaccines market has been analyzed from three perspectives:  vaccine type, product type, and region 

Global Pneumococcal Vaccines Market by Vaccine Type 

[12121]

Based on vaccine type the global pneumococcal vaccine market is classified into pneumococcal conjugate vaccine (PCV), and pneumococcal polysaccharide vaccine (PPSV/PPV). The pneumococcal conjugate vaccine has the highest stake in the market. The factors influencing the growth of conjugate vaccine are that it provides greater immunogenicity than polysaccharide vaccines, greater acceptance among physicians, and better usability in children aged 6 weeks to 5 years. Furthermore, in polysaccharide vaccines, the sugar part of the bacteria as well as the capsule are mixed into the antigen to elicit immune responses. Whereas in conjugate vaccine the sugar is associated with the carrier protein. The carrier protein stimulates another part of immune system which is linked to innate immunity, resulting in a strong immune response. The pneumococcal polysaccharide vaccine is also expected to show a steady rise in demand during the forecast period. As this vaccine is recommended mostly to aged population who are more susceptible to pneumococcal infections, also it is recommended for its long-term effects. In addition, polysaccharide vaccines provide excellent protection against serious pneumococcal infections.

Global Pneumococcal Vaccines Market by Product Type 

Based on product, the global pneumococcal vaccines market is segmented into Prevnar 13, Synflorix and Pneumovax 23. Among these Prevnar 13 has the highest stake in the global market. Prevenar 13 is available as an injection suspension containing parts from 13 different strains of the bacterium Streptococcus pneumoniae delivering better safety against the infection. Other factor such usability in all age groups also makes this product have greater uptake. Other segments are also expected to show significant rise in the forecast period. Synflorix provides booster vaccinations, And Pneumovax 23 is used for preventing infections caused by pneumococcus bacteria. Pneumovax 23 consists of antibodies, which helps in pneumococci opsonization, phagocytosis, and killing by leukocytes. 

Global Pneumococcal Vaccines Market by Region 

Geographically, the global pneumococcal vaccines market has been segmented into North America, Europe, Asia Pacific, and the Rest of the World. The North America has dominated the global market. presence of key market players in the region, greater awareness, and high number of patients are supporting the leading position of North America. According to the National Foundation for Infectious Diseases (US), pneumococcal pneumonia hospitalizes approximately 150,000 people in the United States each year, wherein deaths are 5-7 percent. The death rate is even higher among people aged 65 and older, as well as those with certain medical conditions or other risk factors. Market players in this region are engaged in new product developments. For instance, in June and July 2021, the U.S. FDA (Food and Drug Administration) approved two pneumococcal vaccines for adults: Pneumococcal 20 -valet conjugate vaccine called Prevnar 20 by Pfizer, and 15 valet conjugate vaccine Vaxneuvance by Merck, respectively. Europe is the second largest stakeholder in the global market due to high number of patients, and increased government support. According to the NCBI (National Center of Biotechnology Information), in Spain, the incidence of invasive pneumococcal disease (IPD) was 15.08 per 100,000 people, compared to 2.56 per 100,000 people in Italy. Asia Pacific is also expected to show higher growth in the forecast period due to increased growing penetration of market giants in the region, improving healthcare infrastructure and growing awareness with increasing number of patients. 

Competitive Landscape

Some of the prominent players operating in the pneumococcal vaccines market are  

• Astellas Pharma Inc.
• GlaxoSmithKline Plc.
• Merck & Co. Inc.
• Panacea Biotech Ltd.
• Pfizer Inc.
• Sanofi S.A.
• Walvax Biotechnology Co. Ltd
• CSL Ltd.
• Serum Institute of India Pvt. Ltd.
• Talley Group Limited 

Strategic Developments

In June 2021, Prevnar 20 tm (Pneumococcal 20-valent Conjugate Vaccine) was approved by the U.S. Food and Drug Administration (FDA) for the prevention of invasive disease and pneumonia caused by the vaccine's 20 Streptococcus pneumoniae (pneumococcus) serotypes in adults 18 years and older.

Frequently Asked Questions About This Report